Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)
前瞻性 MIRINAE 试验(一项随机 II 期试验,比较辅助阿特珠单抗联合卡培他滨与卡培他滨单药治疗;KCSG-BR18-21)中,对新辅助化疗后残留的浸润性三阴性乳腺癌进行基因组和转录组分析。
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105804
Im, S-A; Park, K; Koh, J; Park, C; Jung, K H; Lee, J; Ahn, H K; Lee, A; Sim, S H; Kim, M H; Kim, J H; Kim, J H; Lee, K E; Park, K H; Bae, J; Lee, M H; Lim, S; Kim, H J; Lee, D-W; Jeong, J H; Lee, K S; Sohn, J; Suh, K J; Kim, J-Y; Cha, Y J; Moon, J; Ock, C-Y; Kim, S-B; Shin, K; Chae, H; Kim, G M; Lee, K-H; Park, W-Y; Park, Y H; Park, I H